PL372096A1 - Metoda leczenia zaburzeń czynności seksualnych przez związki będące agonistami receptorów delta opioidowych - Google Patents

Metoda leczenia zaburzeń czynności seksualnych przez związki będące agonistami receptorów delta opioidowych

Info

Publication number
PL372096A1
PL372096A1 PL03372096A PL37209603A PL372096A1 PL 372096 A1 PL372096 A1 PL 372096A1 PL 03372096 A PL03372096 A PL 03372096A PL 37209603 A PL37209603 A PL 37209603A PL 372096 A1 PL372096 A1 PL 372096A1
Authority
PL
Poland
Prior art keywords
receptor agonist
opioid receptor
delta opioid
sexual dysfunctions
agonist compounds
Prior art date
Application number
PL03372096A
Other languages
English (en)
Inventor
Kwen-Jen Chang
Klim King
Kestutis P. Biciunas
Robert W. Mcnutt
William Pendergast
Shyi-Tai Jan
Original Assignee
Ardent Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardent Pharmaceuticals, Inc. filed Critical Ardent Pharmaceuticals, Inc.
Publication of PL372096A1 publication Critical patent/PL372096A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03372096A 2002-01-02 2003-01-02 Metoda leczenia zaburzeń czynności seksualnych przez związki będące agonistami receptorów delta opioidowych PL372096A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34521602P 2002-01-02 2002-01-02

Publications (1)

Publication Number Publication Date
PL372096A1 true PL372096A1 (pl) 2005-07-11

Family

ID=23354077

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372096A PL372096A1 (pl) 2002-01-02 2003-01-02 Metoda leczenia zaburzeń czynności seksualnych przez związki będące agonistami receptorów delta opioidowych

Country Status (7)

Country Link
US (6) US8575169B2 (pl)
EP (1) EP1469850B1 (pl)
AU (1) AU2003214800A1 (pl)
NO (1) NO20043240L (pl)
PL (1) PL372096A1 (pl)
TW (1) TW200301701A (pl)
WO (1) WO2003057223A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476280B2 (en) 2002-05-09 2013-07-02 Versi Group, Llc Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
WO2004043365A2 (en) * 2002-11-06 2004-05-27 Azaya Therapeutics, Inc. Method for treatment of premature ejaculation in humans
US7314880B2 (en) 2003-01-02 2008-01-01 Mount Cook Biosciences, Inc. Cardioprotective delta opioid receptor agonists and methods of using same
KR20140015122A (ko) 2003-10-01 2014-02-06 아돌로 코포레이션 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
CN101198330A (zh) * 2005-04-14 2008-06-11 蒙特库克生物科学公司 新阿片类化合物的组合物及其使用方法
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
IT1396951B1 (it) 2009-12-18 2012-12-20 Neuroscienze Pharmaness S C A R L Composti farmaceutici
JP5841529B2 (ja) 2010-05-27 2016-01-13 あすか製薬株式会社 複素環化合物及びｈ１受容体拮抗剤
CN105338962A (zh) * 2013-03-12 2016-02-17 应用生物学研究有限公司 用于改善的药物递送的螯合栓剂
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
EP3436013A4 (en) 2016-03-31 2019-11-13 Versi Group, LLC DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHOD FOR TREATING MORBUS PARKINSON
DE102017215686A1 (de) 2017-09-06 2019-03-07 Tridonic Gmbh & Co Kg Bewegungssensorvorrichtung, verfahren zum betreiben einer bewegungssensorvorrichtung und beleuchtungssystem

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3453285A (en) 1967-11-29 1969-07-01 Miles Lab Tetrazolyl alkanoic acids
US5063929A (en) 1989-08-25 1991-11-12 Staodyn, Inc. Electronic stimulating device having timed treatment of varying intensity and method therefor
US5151448A (en) 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5807858A (en) 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US20020052007A1 (en) 1992-02-03 2002-05-02 Chang Kwen Jen Diarylmethylbenzylpiperazines and corresponding halobenzyl derivatives
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5574159A (en) 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
EP0585500A1 (en) 1992-09-04 1994-03-09 Merrell Dow Pharmaceuticals Inc. Diaryl piperazineacetamides as antimuscarinic agents
US5276042A (en) 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
WO1995004051A1 (en) 1993-07-30 1995-02-09 The Wellcome Foundation Limited Piperazine compounds used in therapy
US5587167A (en) 1993-09-14 1996-12-24 Choi; Hyung K. Pharmaceutical composition for prophylaxis and treatment of premature ejaculation
IT1264965B1 (it) 1993-11-12 1996-10-17 Giorgio Cavallini Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
JPH07247274A (ja) 1994-03-10 1995-09-26 Wakamoto Pharmaceut Co Ltd ピバル酸 テトラゾリルフェニルエステル誘導体、それらを有効成分として含有するエラスターゼ阻害剤及び肺障害治療剤
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
HUP9902160A3 (en) 1996-03-29 2001-02-28 Pfizer Benzyl(idene)-lactam derivatives, their use as selective (ant)agonists of 5-ht1a-and/or 5-ht1d receptors, pharmaceutical compositions containing these compounds
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
EP0942728A1 (en) 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating sexual dysfunction
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
GB9804734D0 (en) 1998-03-05 1998-04-29 Pfizer Ltd Compounds
SE9904675D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE0001207D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0001208D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0001209D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
NZ528935A (en) 2001-03-16 2004-10-29 Dmi Biosciences Inc Method of delaying ejaculation

Also Published As

Publication number Publication date
WO2003057223A9 (en) 2004-04-29
TW200301701A (en) 2003-07-16
US20030186872A1 (en) 2003-10-02
US20130053326A9 (en) 2013-02-28
NO20043240L (no) 2004-08-02
US20120220601A1 (en) 2012-08-30
US8865721B2 (en) 2014-10-21
WO2003057223A8 (en) 2004-07-29
US20160200689A1 (en) 2016-07-14
EP1469850B1 (en) 2013-01-02
AU2003214800A1 (en) 2003-07-24
US8551998B2 (en) 2013-10-08
AU2003214800A8 (en) 2003-07-24
EP1469850A1 (en) 2004-10-27
US20140031367A1 (en) 2014-01-30
US8575169B2 (en) 2013-11-05
US20070173515A1 (en) 2007-07-26
US9296707B2 (en) 2016-03-29
WO2003057223A1 (en) 2003-07-17
US20150018372A1 (en) 2015-01-15
EP1469850A4 (en) 2008-03-12

Similar Documents

Publication Publication Date Title
SG165998A1 (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
WO2005107726A3 (en) Method for the treatment of back pain
WO2003057223A8 (en) Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
WO2004035083A3 (en) Compositions for the treatment of autoimmune disorders
PT1530469E (pt) Forma de dosagem transdérmica que compreende um agente activo, um sal e uma forma de base livre de um antagonista
BR0306919A (pt) Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
WO2003070191A8 (en) Tamper-resistant transdermal opioid delivery devices
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
MX2009009133A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona.
CY1109031T1 (el) Τριαζασπιρο ενωσεις χρησιμες για την αντιμετωπιση ή προληψη πονου
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
SG153661A1 (en) Formulation and methods for the treatment of thrombocythemia
WO2006049933A3 (en) Compositions and methods for the treatment of obesity and sexual dysfunction
WO2006047392A3 (en) Nicotinic-opioid synergy for analgesia
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO2004043365A3 (en) Method for treatment of premature ejaculation in humans
WO2005092442A3 (en) Method and compositions for treatment of chronic neuropathic pain
EP1260221A3 (en) Combination treatment for depression and anxiety
WO2006060736A3 (en) A composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
UA86009C2 (ru) 4-тетразолил-4-фенилпиперидиновые производные для лечения боли
TNSN05114A1 (en) 4-tetrazolyl -4 phenylpiperidine derivatives for treating pain

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)